What's Happening?
The U.S. Food and Drug Administration (FDA) has cleared the Fresenius multiFiltratePRO System for regional citrate anticoagulation in critical care settings. This marks the first time a continuous kidney replacement therapy system and its dedicated solutions,
Cienby (sodium citrate) and Calrezdy (calcium chloride), have received FDA clearance for on-label regional citrate anticoagulation using the Ci-Ca Protocol during CVVHD and CVVHDF in the United States. Previously, this method was standard practice in Europe and Asia-Pacific, but U.S. critical care teams treating acute kidney injury lacked an FDA-cleared system specifically designed for it. The multiFiltratePRO system integrates citrate and calcium pumps, which automatically adjust infusion rates, simplifying a process that previously required separate external pumps. The U.S. rollout will begin with a controlled launch before becoming fully available, with the system showcased at ASN Kidney Week 2026.
Why It's Important?
This FDA clearance is significant for U.S. critical care, particularly for patients with acute kidney injury. Regional citrate anticoagulation has been shown to extend filter life in continuous kidney replacement therapy, with a multicenter randomized controlled trial indicating a mean filter life of 47 hours with citrate compared to 27 hours with systemic heparin. Longer filter life is crucial in intensive care units as it reduces treatment interruptions for critically ill patients. The integrated system of the multiFiltratePRO streamlines the process, potentially improving operational efficiency and patient care. However, the use of Cienby carries safety requirements, including monitoring for hypocalcemia, hypercalcemia, hypernatremia, and hypomagnesemia, and is contraindicated for patients with severely impaired citrate metabolism. The approval provides a defined protocol framework, moving away from institution-specific adaptations for off-label citrate use.
What's Next?
Following the controlled launch, the Fresenius multiFiltratePRO System will become fully available across the U.S. The key metric to observe will be the speed at which U.S. hospitals update their anticoagulation protocols to adopt the now-labeled Ci-Ca approach, transitioning from heparin or off-label citrate use. The adoption rate will determine whether the clinical advantages of extended filter life translate into measurable outcomes data for American ICU patients. Healthcare providers will need to integrate the new system and its associated protocols, including stringent monitoring for potential side effects, into their standard practices. The availability of an FDA-cleared system is expected to standardize and potentially improve the quality of care for acute kidney injury patients requiring continuous kidney replacement therapy.
Beyond the Headlines
The FDA's clearance of the multiFiltratePRO system highlights a broader trend in medical technology towards integrating complex treatment protocols into user-friendly, automated systems. This not only enhances safety through standardized, on-label use but also addresses the operational challenges faced by critical care teams. The shift from off-label use to an FDA-cleared protocol could reduce variability in patient outcomes and improve data collection for future research. Furthermore, it underscores the importance of regulatory bodies in facilitating the adoption of established international best practices within the U.S. healthcare system, potentially setting a precedent for other medical innovations. The ethical implications of managing complex anticoagulation, particularly with the risks of electrolyte imbalances, will continue to be a focus for clinicians, even with the enhanced safety features of the new system.
